We are experienced in the diagnosis and treatment of all liver diseases, with precise plans tailored for each patient to produce the best outcomes.Learn More
We work closely with patients to create a customized nutrition plan to promote weight loss and manage obesity-related liver disease.Learn More
We are a world-class research institute, actively engaged in extensive clinical trials that keep us at the forefront of discovery and innovative new treatments.Learn More
Discover different diseases that affect the liver and see how AZ Liver Health can provide the correct diagnosis.
Fibroscan is non-invasive and painless. The probe presses against the skin near your rib cage and measures a 3 cm3 volume of liver tissue.
A mechanical shear wave flows through the liver and the examination volume is 100 x the size of a typical liver biopsy and minimizes sampling error.
Vibrations capture liver stiffness and attenuation levels to determine the extent of fat levels within the liver tissue. Results are shared with your doctor.
AZ Liver’s own Vicki McIntyre, DNP, FNP was featured on the popular Tucson morning show “The Morning Blend” last month where she discussed several topics including:
Abstract: Hepatitis C virus (HCV) infection is the leading reason for liver transplantation and a common cause of hepatocellular carcinoma, the most rapidly increasing cause of cancer-related deaths…
Watch author, Anita Kohli, MD, discuss “Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse. An Open-Label Pilot Study.”
Join GP and Medical Educator Dr Sam Manger MBBS BSc FRACGP FASLM covering a variety of topics with case studies, guideline reviews, guest interviews and more for medical doctors and allied…
If you’re a liver patient, your diet is adjusted to meet your individual needs. Talk to your doctor about what’s best for you. Still, here are some general food tips for a healthy or healthier liver:
Our very own Ann Moore joins Wayne Eskridge to discuss advances in liver disease screening technology.
The interferon (IFN)–free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. However, sofosbuvir plus ribavirin therapy is associated with relapse in 15% to 30% of patients with HCV GT-1.
Abstract: Hepatitis C virus (HCV) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler therapeutics using direct-acting antivirals that target various stages of the HCV life cycle are in development to eradicate HCV without concomitant interferon.